Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/12/22 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
46 | |
| 05/11/22 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
44 | |
| 11/12/21 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
52 | |
| 08/13/21 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
108 | |
| 05/14/21 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
52 | |
| 11/13/20 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
61 | |
| 08/10/20 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
53 | |
| 05/15/20 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
89 | |
| 11/08/19 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
48 | |
| 08/08/19 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
77 |